Trials / Completed

CompletedNCT01038297

Safety and Efficacy Study of Different Dose Levels of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, WITHIN-SUBJECT CONTROLLED, DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF EXC 001 FOR THE TREATMENT OF INCISION SCARS IN THE PANNUS OF SUBJECTS UNDERGOING AN ELECTIVE ABDOMINOPLASTY

Status: Completed
Phase: Phase 2
Study type: Interventional
Enrollment: 30 (actual)

Sponsor: Pfizer · Industry
Sex: Female
Age: 18 Years – 45 Years
Healthy volunteers: Accepted

Summary

This study will compare how well EXC 001 works versus placebo in reducing the appearance of scars in subjects undergoing elective abdominoplasty. The study will also evaluate the safety of EXC 001 in healthy adult subjects.

Conditions

Scar Prevention

Interventions

Type	Name	Description
DRUG	EXC 001	Intradermal injections of EXC 001 and placebo given on various schedules.
DRUG	Placebo	Intradermal injections of EXC 001 and placebo given on various schedules.

Timeline

Start date: 2009-12-01
Primary completion: 2010-07-07
Completion: 2010-07-07
First posted: 2009-12-23
Last updated: 2021-09-20
Results posted: 2021-09-20

Locations

2 sites across 1 country: United States

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT01038297. Inclusion in this directory is not an endorsement.